TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis

Nicole J. Lake, Rachael L. Taylor, Hugh Trahair, K. N. Harikrishnan, Joanne E. Curran, Marcio Almeida, Hemant Kulkarni, Nigora Mukhamedova, Anh Hoang, Hann Low, Andrew J. Murphy, Matthew P. Johnson, Thomas D. Dyer, Michael C. Mahaney, Harald H.H. Göring, Eric K. Moses, Dmitri Sviridov, John Blangero, Jeremy B.M. Jowett, Kiymet Bozaoglu

    Research output: Contribution to journalArticlepeer-review

    12 Scopus citations

    Abstract

    Aims The recent failures of HDL-raising therapies have underscored our incomplete understanding of HDL biology. Therefore there is an urgent need to comprehensively investigate HDL metabolism to enable the development of effective HDL-centric therapies. To identify novel regulators of HDL metabolism, we performed a joint analysis of human genetic, transcriptomic, and plasma HDL-cholesterol (HDL-C) concentration data and identified a novel association between trafficking protein, kinesin binding 2 (TRAK2) and HDL-C concentration. Here we characterize the molecular basis of the novel association between TRAK2 and HDL-cholesterol concentration. Methods and results Analysis of lymphocyte transcriptomic data together with plasma HDL from the San Antonio Family Heart Study (n = 1240) revealed a significant negative correlation between TRAK2 mRNA levels and HDL-C concentration, HDL particle diameter and HDL subspecies heterogeneity. TRAK2 siRNA-mediated knockdown significantly increased cholesterol efflux to apolipoprotein A-I and isolated HDL from human macrophage (THP-1) and liver (HepG2) cells by increasing the mRNA and protein expression of the cholesterol transporter ATP-binding cassette, sub-family A member 1 (ABCA1). The effect of TRAK2 knockdown on cholesterol efflux was abolished in the absence of ABCA1, indicating that TRAK2 functions in an ABCA1-dependent efflux pathway. TRAK2 knockdown significantly increased liver X receptor (LXR) binding at the ABCA1 promoter, establishing TRAK2 as a regulator of LXR-mediated transcription of ABCA1. Conclusion We show, for the first time, that TRAK2 is a novel regulator of LXR-mediated ABCA1 expression, cholesterol efflux, and HDL biogenesis. TRAK2 may therefore be an important target in the development of antiatherosclerotic therapies.

    Original languageEnglish (US)
    Pages (from-to)3579-3587
    Number of pages9
    JournalEuropean Heart Journal
    Volume38
    Issue number48
    DOIs
    StatePublished - Dec 21 2017

    Keywords

    • ABCA1
    • Atherosclerosis
    • Cholesterol
    • Genetics
    • HDL
    • TRAK2

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint Dive into the research topics of 'TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis'. Together they form a unique fingerprint.

    Cite this